Michael Schmitz
Stock Analyst at Guggenheim
(2.89)
# 1,502
Out of 5,124 analysts
8
Total ratings
87.5%
Success rate
22.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $3.72 | +34.41% | 1 | Nov 14, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $28.93 | - | 1 | Nov 14, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $30.80 | +39.61% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $43.83 | +2.67% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $79.65 | +2.95% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $11.86 | +237.27% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $0.98 | - | 1 | Jan 3, 2023 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $3.72
Upside: +34.41%
Mersana Therapeutics
Nov 14, 2025
Downgrades: Neutral
Price Target: n/a
Current: $28.93
Upside: -
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $30.80
Upside: +39.61%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $43.83
Upside: +2.67%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $79.65
Upside: +2.95%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $11.86
Upside: +237.27%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.98
Upside: -